Ernexa Therapeutics Inc. Letters of Credit Outstanding, Amount
Ernexa Therapeutics Inc. (ERNA) had Letters of Credit Outstanding, Amount of $250.00 thousand as of 2018-08-31, per its 10-Q filed 2018-11-09.
Discontinued › Notes › Other Liabilities › Other Liabilities and Financial Instruments Subject to Mandatory Redemption
us-gaap:LettersOfCreditOutstandingAmount · last filed 2018-11-09
- 2018-08-31: Letters of Credit Outstanding, Amount $250.00K.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2018-08-31 | $250.00K 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |